There is an urgent need for effective therapeutic agents against human immunodeficiency virus 1 (HIV-1), the causative agent of acquired immunodeficiency syndrome (AIDS). This project will result in the development of ribozymes that will selectively attack and destroy HIV RNA within an infected cell. Ribozymes are catalytic RNA molecules; many catalyze site-specific RNA cleavage reactions. The molecular basis for substrate selectivity is understood for some ribozymes. Therefore, it is possible to rationally alter the substrate specificity of a ribozyme by engineering changes within its substrate binding site using recombinant/synthetic DNA methods.
The Specific Aims of this proposal are to (1) Develop and characterize ribozymes that selectively attack several HIV-1 RNA sequences, (2) Assemble and evaluate multivalent ribozymes against HIV-1 RNA, (3) Develop a bacteriophage system for analyzing and optimizing antiviral activity of ribozymes in vivo, (4) Use the bacteriophage system for surrogate genetic enrichment of optimized anti-HIV ribozymes, and (5) Evaluate the activity of resulting monovalent and multivalent anti-HIV ribozymes in T cell extracts. Ribozymes for this study will be derived from the self-cleaving """"""""hairpin"""""""" minus strand of tobacco ringspot virus satellite ((-)sTRSV). In preliminary work, we have generated a hairpin ribozyme that selectively attacks HIV-1 pol sequences. Advantages of anti-HIV ribozymes are several: (i) Ribozymes can potentially inhibit HIV infection of cells and also inhibit HIV gene expression within infected cells, (ii) Ribozymes may be highly selective agents, (iii) Ribozymes act catalytically, so that a single molecule of ribozyme can potentially destroy many molecules of HIV RNA, and (iv) Ribozymes are not susceptible to pleiotropic drug resistance. This project will directly address major challenges in the development of optimal anti-HIV ribozymes---to achieve the optimal balance of sequence selectivity, catalytic activity and ribozyme stability under conditions encountered in vivo.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI029892-05
Application #
2065292
Study Section
Special Emphasis Panel (ARR (V1))
Project Start
1990-07-01
Project End
1995-04-30
Budget Start
1994-05-01
Budget End
1995-04-30
Support Year
5
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Vermont & St Agric College
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
066811191
City
Burlington
State
VT
Country
United States
Zip Code
05405
Yu, Q; Pecchia, D B; Kingsley, S L et al. (1998) Cleavage of highly structured viral RNA molecules by combinatorial libraries of hairpin ribozymes. The most effective ribozymes are not predicted by substrate selection rules. J Biol Chem 273:23524-33
Berzal-Herranz, A; Burke, J M (1997) Ligation of RNA molecules by the hairpin ribozyme. Methods Mol Biol 74:349-55
Sargueil, B; Pecchia, D B; Burke, J M (1995) An improved version of the hairpin ribozyme functions as a ribonucleoprotein complex. Biochemistry 34:7739-48
Joseph, S; Burke, J M (1993) Optimization of an anti-HIV hairpin ribozyme by in vitro selection. J Biol Chem 268:24515-8